




PATIENT ENGAGEMENT SERVICES  
RARE DISEASES AND DISORDERS EXPERTISE

OVERVIEW



INDICATIONS

- > Atrial Fibrillation, Familial
- > Epilepsy
- > G6PD Enzyme Deficiency/Acne
- > Idiopathic Pulmonary Fibrosis
- > Idiopathic Pulmonary Hypertension
- > Juvenile Rheumatoid Arthritis
- > Lysosomal Acid Lipase Deficiency
- > Mantle Cell Lymphoma
- > Multiple Myeloma
- > Myasthenia Gravis
- > Non Small-Cell Lung Cancer
- > Optic Neuritis
- > Osteonecrosis
- > Raynaud's Phenomenon (CREST Syndrome)

COUNTRIES

- > Argentina
- > Australia
- > Austria
- > Brazil
- > Bulgaria
- > Canada
- > Chile
- > Colombia
- > Costa Rica
- > Croatia
- > Czech Republic
- > Denmark
- > Egypt
- > Finland
- > France
- > Germany
- > Greece
- > Guatemala
- > Hong Kong
- > Hungary
- > India
- > Indonesia
- > Ireland
- > Israel
- > Italy
- > Japan
- > Korea
- > Lithuania
- > Mexico
- > Netherlands
- > New Zealand
- > Norway
- > Panama
- > Peru
- > Philippines
- > Poland
- > Russian Federation
- > Singapore
- > South Africa
- > Spain
- > Sweden
- > Switzerland
- > Taiwan
- > Thailand
- > Turkey
- > Ukraine
- > United Kingdom
- > United States

PATIENT ENGAGEMENT SERVICES  
RARE DISEASES AND DISORDERS EXPERTISE

CASE STUDY: ACNE VULGARIS WITH G6PD ENZYME DEFICIENCY  
ENGAGEMENT PROGRAM

STUDY DETAILS

- > Phase IV, double-blind, randomized, crossover study with two-week washout period
- > Target population: G6PD-deficient subjects of African-American and Mediterranean descent with acne vulgaris
- > Engagement timeline: Four months

IMPERIAL OBJECTIVES

- > Generate study awareness through a variety of within-practice and external campaigns
- > Facilitate enrollment of 60 G6PD-deficient subjects with acne vulgaris across 30 sites in North America within four months

CAMPAIGN

- > Site support materials (engagement kits)
- > Advertising (radio and print)
- > Monthly site newsletters
- > Coordinator appreciation packages
- > Patient support kits
- > Outreach
- > Call center support
- > Enrollment updates and tips to sites

The initiatives were designed to enhance study visibility and promote engagement enthusiasm among sites and CRAs. Many strategies were directed at facilitating awareness of the study within each site’s own practice. Direct outreach activities, combined with newsletters, weekly engagement tips and coordinator appreciation packages, contributed to attainment of the enrollment goal. Imperial also attributes program success to strong site relationships.

RESULTS

- > 64 patients were randomized within 5 months due to joint efforts among the sponsor, participating sites and Imperial.
- > Imperial initiatives were sustained throughout the program.
- > There was steady enrollment progression through the course of the trial—the cumulative result of engagement support implementation and the level of site activation.

CUMULATIVE ENROLLMENT PROGRESSION

